Individuals with type 2 diabetes and/or obesity plus one or more metabolic risk factors are at higher risk for metabolic dysfunction-associated steatotic liver disease (MASLD) with fibrosis and progression to more severe liver disease, according to new European guidelines that provide recommendations for early diagnosis and management.
Clinicians should be cautious about excessive thyroid screening in patients taking GLP-1 drugs due to the risk of overdiagnosis of thyroid cancer.
A surprisingly high proportion of patients with poorly controlled type 2 diabetes have hypercortisolism, suggesting the need to rethink screening and management approaches for this patient population.
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, improves taste sensitivity, changes brain responses to sweet tastes, and alters the expression of genes associated with taste bud development in women with obesity.
Imbalances in sex hormone ratios, specifically elevated free estradiol index (FEI) and free androgen index (FAI), are linked to increased risk of metabolic syndrome and inflammation across different age groups and genders.
Triptorelin induces varied gonadotropin responses in women with different conditions.